Literature DB >> 8339387

Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

D J Stewart1, D Grewaal, M D Redmond, N Z Mikhael, V A Montpetit, R Goel, R M Green.   

Abstract

Autopsy tissues were collected from ten patients who had received etoposide, 150-3480 mg, from 1 to 412 days antemortem and from five patients who had received teniposide, 234-1577 mg, from 3 to 52 days antemortem. Tissues were assayed for etoposide and teniposide using high-pressure liquid chromatography with electrochemical detection. Etoposide was detectable in tissues of three of four patients dying < 5 days after their last etoposide treatments to cumulative doses of 150-432 (median, 280) mg but was detectable in tissues of only one of six patients dying 7-412 (median, 37) days after their last etoposide treatment to a cumulative dose of 607-3600 (median, 1553) mg. The highest tissue concentrations were in the small bowel, prostate, thyroid, bladder, spleen, and testicle. Intermediate concentrations were found in the lymph node, skeletal muscle, adrenal gland, stomach, tumor, liver, lung, pancreas, and kidney, and the lowest concentrations were found in the heart, brain, diaphragm, vagina, and esophagus. Teniposide was detectable in one patient dying 3 days after a cumulative teniposide dose of 576 mg (spleen, prostate, heart > large bowel, liver, pancreas > thyroid, adrenal, stomach, small bowel, bladder, testicle, and skeletal muscle) but was not detectable in any tissue from four patients dying 5-52 (median, 8) days after their last treatment to a cumulative teniposide dose of 234-1577 (median, 520) mg. The very short tissue half-life contrasts with our previous observations for human autopsy tissue concentrations of mitoxantrone, doxorubicin, menogaril metabolites, diaziquone, and amsacrine. The short tissue half-life may help explain the schedule dependency of epipodophyllotoxin efficacy and may also help explain the lack of visceral toxicity of these compounds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339387     DOI: 10.1007/bf00735921

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

Review 1.  VM 26 and VP 16-213: a comparative analysis.

Authors:  M Rozencweig; D D Von Hoff; J E Henney; F M Muggia
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

2.  Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

Authors:  D J Stewart; M Leavens; M Maor; L Feun; M Luna; J Bonura; R Caprioli; T L Loo; R S Benjamin
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

3.  Platinum concentrations in human autopsy tumor samples.

Authors:  D J Stewart; N Z Mikhael; R C Nair; S Kacew; V Montpetit; A Nanji; J A Maroun; K Howard
Journal:  Am J Clin Oncol       Date:  1988-04       Impact factor: 2.339

4.  Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection.

Authors:  J J Holthuis; F M Römkens; H M Pinedo; W J van Oort
Journal:  J Pharm Biomed Anal       Date:  1983       Impact factor: 3.935

5.  Concentration of vinblastine in human intracerebral tumor and other tissues.

Authors:  D J Stewart; K Lu; R S Benjamin; M E Leavens; M Luna; H Y Yap; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).

Authors:  N Savaraj; K Lu; L G Feun; M E Leavens; D Stewart; M A Burgess; R S Benjamin; T L Loo
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

7.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J M Dennery; R Belanger; J Gerin-Lajoie; V Montpetit; D Nundy; J Prior; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

9.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

Authors:  W Ross; T Rowe; B Glisson; J Yalowich; L Liu
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

10.  Activity and distribution studies of etoposide and mitozolomide in vivo and in vitro against human choriocarcinoma cell lines.

Authors:  C J Brindley; R B Pedley; P Antoniw; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more
  5 in total

1.  Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385).

Authors:  A N Leaf; B C Wolf; J M Kirkwood; R E Haselow
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 2.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs.

Authors:  T Oguri; Y Fujiwara; T Isobe; O Katoh; H Watanabe; M Yamakido
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.

Authors:  E Syahruddin; T Oguri; T Takahashi; T Isobe; Y Fujiwara; M Yamakido
Journal:  Jpn J Cancer Res       Date:  1998-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.